JP Morgan Chase
UTMD icon

JP Morgan Chase’s Utah Medical Products UTMD Stock Holding History

JP Morgan Chase’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.1K Buy
1,530
+25
+2% +$1.57K ﹤0.01% 5842
2025
Q4 		$84.2K Sell
1,505
-36
-2% -$2.09K ﹤0.01% 5977
2025
Q3 		$97K Sell
1,541
-4,612
-75% -$273K ﹤0.01% 5920
2025
Q2 		$350K Sell
6,153
-66,176
-91% -$3.6M ﹤0.01% 4951
2025
Q1 		$4.05M Sell
72,329
-7,374
-9% -$442K ﹤0.01% 3340
2024
Q4 		$4.9M Buy
79,703
+10,292
+15% +$665K ﹤0.01% 3361
2024
Q3 		$4.64M Buy
69,411
+6,645
+11% +$451K ﹤0.01% 3271
2024
Q2 		$4.19M Sell
62,766
-9,786
-13% -$666K ﹤0.01% 3167
2024
Q1 		$5.16M Buy
72,552
+8,924
+14% +$669K ﹤0.01% 3081
2023
Q4 		$5.36M Buy
63,628
+5,362
+9% +$445K ﹤0.01% 3021
2023
Q3 		$5.01M Sell
58,266
-268
-0.5% -$24.7K ﹤0.01% 2845
2023
Q2 		$5.46M Sell
58,534
-26,934
-32% -$2.54M ﹤0.01% 2791
2023
Q1 		$8.1M Buy
85,468
+2,255
+3% +$207K ﹤0.01% 2458
2022
Q4 		$8.37M Sell
83,213
-9,214
-10% -$841K ﹤0.01% 2407
2022
Q3 		$7.88M Sell
92,427
-11,387
-11% -$1.01M ﹤0.01% 2354
2022
Q2 		$8.92M Buy
103,814
+2,045
+2% +$174K ﹤0.01% 2266
2022
Q1 		$9.14M Buy
101,769
+14,693
+17% +$1.35M ﹤0.01% 2465
2021
Q4 		$8.71M Sell
87,076
-6,585
-7% -$672K ﹤0.01% 2572
2021
Q3 		$8.7M Sell
93,661
-2,958
-3% -$261K ﹤0.01% 2509
2021
Q2 		$8.21M Buy
96,619
+32,001
+50% +$2.77M ﹤0.01% 2600
2021
Q1 		$5.6M Sell
64,618
-1,882
-3% -$166K ﹤0.01% 2870
2020
Q4 		$5.61M Buy
66,500
+14,329
+27% +$1.22M ﹤0.01% 2720
2020
Q3 		$4.22M Buy
52,171
+7,251
+16% +$602K ﹤0.01% 2707
2020
Q2 		$3.98M Buy
44,920
+29,182
+185% +$2.62M ﹤0.01% 2628
2020
Q1 		$1.48M Buy
15,738
+12,416
+374% +$1.15M ﹤0.01% 3160
2019
Q4 		$358K Buy
3,322
+2,181
+191% +$221K ﹤0.01% 4411
2019
Q3 		$109K Sell
1,141
-22,408
-95% -$2.08M ﹤0.01% 4871
2019
Q2 		$2.13M Buy
23,549
+1,149
+5% +$96.7K ﹤0.01% 3340
2019
Q1 		$1.98M Sell
22,400
-1,818
-8% -$160K ﹤0.01% 3341
2018
Q4 		$2.01M Sell
24,218
-930
-4% -$81.9K ﹤0.01% 3271
2018
Q3 		$2.37M Buy
25,148
+4,198
+20% +$401K ﹤0.01% 3337
2018
Q2 		$2.31M Sell
20,950
-6,303
-23% -$658K ﹤0.01% 3309
2018
Q1 		$2.69M Sell
27,253
-3,947
-13% -$352K ﹤0.01% 3059
2017
Q4 		$2.54M Sell
31,200
-3,318
-10% -$259K ﹤0.01% 3173
2017
Q3 		$2.58M Buy
34,518
+761
+2% +$54.7K ﹤0.01% 3007
2017
Q2 		$2.44M Sell
33,757
-3,151
-9% -$207K ﹤0.01% 2921
2017
Q1 		$2.3M Buy
36,908
+668
+2% +$42K ﹤0.01% 2958
2016
Q4 		$2.64M Buy
36,240
+7,602
+27% +$494K ﹤0.01% 2891
2016
Q3 		$1.71M Buy
28,638
+5,963
+26% +$379K ﹤0.01% 2886
2016
Q2 		$1.43M Sell
22,675
-2,075
-8% -$134K ﹤0.01% 2981
2016
Q1 		$1.55M Buy
24,750
+2,575
+12% +$152K ﹤0.01% 2832
2015
Q4 		$1.3M Buy
22,175
+6,125
+38% +$347K ﹤0.01% 2993
2015
Q3 		$864K Buy
+16,050
New +$875K ﹤0.01% 3186

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's UTMD Position: Q1 2026 in Review

JP Morgan Chase increased its Utah Medical Products (UTMD) stake by 1.7% in Q1 2026, buying an estimated $1.57K and bringing the position to 1,530 shares worth $99.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5842.

JP Morgan Chase first reported a position in UTMD in Q3 2015 and has held it in 43 quarters since. The position peaked at $9.14M in Q1 2022. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • JP Morgan Chase held 1,530 shares of Utah Medical Products worth $99.1K as of Q1 2026.
  • JP Morgan Chase bought 25 Utah Medical Products shares in Q1 2026, an estimated $1.57K.
  • Utah Medical Products made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5842 holding.
  • JP Morgan Chase first reported a position in Utah Medical Products in Q3 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Utah Medical Products position peaked at $9.14M in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.